Patents by Inventor Rohit Duggal

Rohit Duggal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Generating CIK NKT cells from cord blood
    Patent number: 11931382
    Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.
    Type: Grant
    Filed: July 3, 2022
    Date of Patent: March 19, 2024
    Assignee: ImmunityBio, Inc.
    Inventors: Rohit Duggal, Ranjeet Sinha
  • GENERATING CIK NKT CELLS FROM CORD BLOOD
    Publication number: 20220347218
    Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.
    Type: Application
    Filed: July 3, 2022
    Publication date: November 3, 2022
    Inventors: ROHIT DUGGAL, Ranjeet SINHA
  • Mononuclear cell derived NK cells
    Patent number: 11453862
    Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: September 27, 2022
    Assignee: ImmunityBio, Inc.
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
  • Primary NK CAR Constructs And Methods
    Publication number: 20220282216
    Abstract: Disclosed herein are recombinant nucleic acids, comprising a 5? untranslated (5?-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.
    Type: Application
    Filed: November 26, 2019
    Publication date: September 8, 2022
    Inventors: Fereshteh Parviz, Rohit Duggal
  • Generating CIK NKT cells from cord blood
    Patent number: 11351196
    Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: June 7, 2022
    Assignee: ImmunityBio, Inc.
    Inventors: Rohit Duggal, Ranjeet Sinha
  • GENERATING CIK NKT CELLS FROM CORD BLOOD
    Publication number: 20220133789
    Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.
    Type: Application
    Filed: July 1, 2019
    Publication date: May 5, 2022
    Inventors: Rohit DUGGAL, Ranjeet SINHA
  • CIML NK cells and Methods Therefor
    Publication number: 20210361711
    Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.
    Type: Application
    Filed: July 14, 2021
    Publication date: November 25, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Patrick Soon-Shiong
  • GENERATING CIK NKT CELLS FROM CORD BLOOD
    Publication number: 20210205367
    Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 8, 2021
    Inventors: Rohit DUGGAL, Ranjeet SINHA
  • Mononuclear Cell Derived NK Cells
    Publication number: 20210009954
    Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
    Type: Application
    Filed: February 20, 2020
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
  • Mononuclear Cell Derived NK Cells
    Publication number: 20210009953
    Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
    Type: Application
    Filed: July 8, 2019
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
  • CIML NK cells and Methods Therefor
    Publication number: 20210008107
    Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Patrick Soon-Shiong
  • CIML NK cells and Methods Therefor
    Publication number: 20210008112
    Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.
    Type: Application
    Filed: August 5, 2020
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Patrick Soon-Shiong
  • Inhibitors of Hepatitis C virus, compositions and treatments using the same
    Publication number: 20040229817
    Abstract: The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor, and compositions comprising the same.
    Type: Application
    Filed: February 18, 2004
    Publication date: November 18, 2004
    Applicant: AGOURON PHARMACEUTICALS, INC.
    Inventors: Rohit Duggal, Koleen Jill Herlihy, Wei Liu, Amy Karen Patick, Eiann Sha, Weidong Hao
  • Reporter-selectable Hepatitis C virus replicon
    Publication number: 20040214178
    Abstract: The invention relates to a reporter-selectable hepatitis C virus (HCV) replicon, and use of the replicon to generate stable, human hepatoma cell lines. The replicon and cell lines are useful in the compound screening process in HCV drug discovery.
    Type: Application
    Filed: April 24, 2003
    Publication date: October 28, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Rohit Duggal, Amy Karen Patick, Jie Zhang, Weidong Zhao
  • Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
    Publication number: 20040209246
    Abstract: Methods are provided for evaluating the antiviral activity and cytotoxicity of a compound in the same population of cells by the use of reporter genes and dye reduction methodology. The dual antiviral activity/cytotoxicity reporter methods are amenable for use in a high-throughput format.
    Type: Application
    Filed: April 5, 2004
    Publication date: October 21, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Mary Brothers, Rohit Duggal, Koleen Herlihy, Amy Patick, Weidong Hao